CA2675521C - Human cancer stem cells - Google Patents

Human cancer stem cells Download PDF

Info

Publication number
CA2675521C
CA2675521C CA2675521A CA2675521A CA2675521C CA 2675521 C CA2675521 C CA 2675521C CA 2675521 A CA2675521 A CA 2675521A CA 2675521 A CA2675521 A CA 2675521A CA 2675521 C CA2675521 C CA 2675521C
Authority
CA
Canada
Prior art keywords
stem cells
cells
cell
cancer stem
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2675521A
Other languages
English (en)
French (fr)
Other versions
CA2675521A1 (en
Inventor
Jennie P. Mather
Penelope Roberts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Raven Biotechnologies Inc
Original Assignee
Raven Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raven Biotechnologies Inc filed Critical Raven Biotechnologies Inc
Publication of CA2675521A1 publication Critical patent/CA2675521A1/en
Application granted granted Critical
Publication of CA2675521C publication Critical patent/CA2675521C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0695—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2675521A 2007-01-22 2008-01-22 Human cancer stem cells Expired - Fee Related CA2675521C (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US88149707P 2007-01-22 2007-01-22
US60/881,497 2007-01-22
US90718007P 2007-03-23 2007-03-23
US60/907,180 2007-03-23
US92424707P 2007-05-04 2007-05-04
US60/924,247 2007-05-04
US95071407P 2007-07-19 2007-07-19
US60/950,714 2007-07-19
US97261307P 2007-09-14 2007-09-14
US60/972,613 2007-09-14
PCT/US2008/051730 WO2008091908A2 (en) 2007-01-22 2008-01-22 Human cancer stem cells

Publications (2)

Publication Number Publication Date
CA2675521A1 CA2675521A1 (en) 2008-07-31
CA2675521C true CA2675521C (en) 2016-04-26

Family

ID=39641454

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2675521A Expired - Fee Related CA2675521C (en) 2007-01-22 2008-01-22 Human cancer stem cells

Country Status (9)

Country Link
US (1) US8309354B2 (https=)
EP (1) EP2109668A4 (https=)
JP (1) JP2010516259A (https=)
KR (1) KR101523698B1 (https=)
CN (1) CN101855339A (https=)
AU (1) AU2008207945A1 (https=)
CA (1) CA2675521C (https=)
IL (1) IL199836A (https=)
WO (1) WO2008091908A2 (https=)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101523698B1 (ko) 2007-01-22 2015-05-29 마크로제닉스 웨스트 인코퍼레이티드 사람 암 줄기세포
CN102203290B (zh) 2008-10-27 2015-05-06 北海道公立大学法人札幌医科大学 肿瘤干细胞分子标记
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011078301A1 (ja) 2009-12-25 2011-06-30 ファーマロジカルズ・リサーチ プライベート リミテッド Nog樹立癌細胞株が移植された非ヒト動物モデルを用いた抗癌剤ターゲット探索及びスクリーニング法
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
JP5998060B2 (ja) 2010-03-04 2016-09-28 マクロジェニクス，インコーポレーテッド Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
WO2011129348A1 (ja) * 2010-04-13 2011-10-20 株式会社Ｒｅｉメディカル 癌組織由来細胞塊または癌細胞凝集塊から得られる癌治療用組成物およびそれを用いた免疫療法剤の製造方法ならびに免疫療法効果評価方法
EP2596119B8 (en) 2010-07-23 2021-06-02 Astellas Institute for Regenerative Medicine Methods for detection of rare subpopulations of cells and highly purified compositions of cells
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
EP2611463A2 (en) 2010-09-03 2013-07-10 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
CA2810016A1 (en) * 2010-09-03 2012-03-08 Stem Centrx, Inc. Novel modulators and methods of use
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
JP6230789B2 (ja) * 2010-10-06 2017-11-15 中外製薬株式会社 癌幹細胞集団及びその作製方法
WO2012118547A1 (en) 2010-12-08 2012-09-07 Stem Centrx, Inc. Novel modulators and methods of use
KR101182549B1 (ko) * 2010-12-16 2012-09-12 엘지이노텍 주식회사 3차원 입체 카메라 모듈
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
ES2586599T3 (es) * 2011-03-24 2016-10-17 The Rogosin Institute Ensayo para cribar compuestos que disminuyen selectivamente el número de células madre de cáncer
DK2714733T3 (da) 2011-05-21 2019-05-06 Macrogenics Inc Cd3-bindende molekyler, der er i stand til at binde til human og ikke-human cd3
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
JP6077997B2 (ja) * 2011-09-07 2017-02-08 中外製薬株式会社 癌幹細胞の分離
US20140302511A1 (en) 2011-10-28 2014-10-09 Pharmalogicals Research Pte. Ltd. Cancer stem cell-specific molecule
US10247731B2 (en) 2012-02-22 2019-04-02 Verik Bio, Inc. System for immunotherapy targeting tumor propagation and progression
CA2865415C (en) 2012-02-24 2022-06-21 Stem Centrx, Inc. Anti sez6 antibodies and methods of use
PE20190658A1 (es) 2012-02-24 2019-05-08 Abbvie Stemcentrx Llc Moduladores y metodos de empleo novedosos
JP6090735B2 (ja) * 2012-03-02 2017-03-08 国立大学法人山口大学 消化器系がん幹細胞を培養するための無血清培地、及びそれを用いた消化器系がん幹細胞の増殖方法
CA3223380A1 (en) * 2012-03-19 2013-09-26 Stemline Therapeutics, Inc. Methods for treating and monitoring the status of cancer
DK3536334T3 (da) 2012-05-16 2021-09-13 Stemline Therapeutics Inc Cancer stamcelle målrettede cancer vacciner
WO2014165101A1 (en) * 2013-03-13 2014-10-09 California Stem Cell, Inc. Individualized high purity colon carcinoma stem cells, methods and use of the same
BR112015019909A2 (pt) 2013-02-22 2017-08-29 Abbvie Stemcentrx Llc Conjugados anticorpo-fármaco, composição farmacêutica, usos dos mesmos, e kit
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
TWI659210B (zh) * 2013-08-12 2019-05-11 Minerva Biotechnologies Corporation 加強腫瘤生長的方法
AU2014312215B2 (en) 2013-08-28 2020-02-27 Abbvie Stemcentrx Llc Site-specific antibody conjugation methods and compositions
AU2014312310A1 (en) 2013-08-28 2016-04-07 Abbvie Stemcentrx Llc Novel SEZ6 modulators and methods of use
US9782476B2 (en) 2013-09-06 2017-10-10 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
PE20160870A1 (es) 2013-11-06 2016-09-09 Abbvie Stemcentrx Llc Anticuerpos anti-claudina novedosos y metodos de uso
PE20160993A1 (es) 2013-12-12 2016-10-14 Abbvie Stemcentrx Llc Nuevos anticuerpos anti-dpep3 y metodos de uso
PE20161209A1 (es) 2014-02-21 2016-11-10 Abbvie Stemcentrx Llc Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma
KR20170003720A (ko) 2014-05-27 2017-01-09 아카데미아 시니카 항-ｃｄ20 글리코항체 및 이의 용도
CA2950423A1 (en) 2014-05-27 2015-12-03 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR102512592B1 (ko) 2014-05-27 2023-03-21 아카데미아 시니카 항-ｈｅｒ2 글리코항체 및 이의 용도
CN106714829A (zh) 2014-05-28 2017-05-24 中央研究院 抗TNF‑α醣抗体及其用途
CN106537148B (zh) * 2014-06-25 2019-10-11 泰尔哈绍梅尔医学研究基础设施和服务有限公司 癌症干细胞的鉴定及其用于诊断和治疗的用途
US20170191034A1 (en) * 2014-09-04 2017-07-06 Agency For Science Technology And Research A method to up-regulate cancer stem cell markers for the generation of antigen specific cytotoxic effector t cells
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
JP2018510844A (ja) * 2015-01-24 2018-04-19 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ がんマーカーおよびその使用方法
SG11201706024YA (en) 2015-01-26 2017-08-30 Macrogenics Inc Multivalent molecules comprising dr5-binding domains
KR20160109356A (ko) 2015-03-11 2016-09-21 이화여자대학교 산학협력단 자가 면역 질환 예방 또는 치료용 조성물
KR20160109358A (ko) 2015-03-11 2016-09-21 이화여자대학교 산학협력단 면역 질환 예방 또는 치료용 조성물
KR102036029B1 (ko) 2015-03-11 2019-10-24 이화여자대학교 산학협력단 골수 부전 예방 또는 치료용 조성물
JP6161828B2 (ja) * 2015-04-20 2017-07-12 国立大学法人 岡山大学 がんの非ヒトモデル動物及びその作製方法、がん幹細胞及びその製造方法
EP3208331A1 (en) * 2016-02-17 2017-08-23 PromoCell bioscience alive GmbH Biomedizinische Produkte Chemically defined medium for the culture of cancer stem cell (csc) containing cell populations
TWI781098B (zh) 2016-04-15 2022-10-21 美商宏觀基因股份有限公司 新穎的ｂ７-ｈ３-結合分子、其抗體藥物綴合物及其使用方法
EP3454864A4 (en) 2016-04-21 2021-01-13 Abbvie Stemcentrx LLC Novel anti-bmpr1b antibodies and methods of use
EP3500594A4 (en) 2016-08-22 2020-03-11 Cho Pharma Inc. ANTIBODIES, BINDING FRAGMENTS AND METHOD FOR USE
GB201700952D0 (en) * 2017-01-19 2017-03-08 Univ Cape Town In vitro propagation of primary cancer cells
CN107904206A (zh) * 2017-11-17 2018-04-13 张家港澳洋医院有限公司 一种脂多糖诱导肿瘤细胞生成肿瘤干细胞的用途和方法
AU2019284405B2 (en) * 2018-06-13 2025-08-21 Genex Health Co.,Ltd Colorectal cancer solid tumour primary cell and colorectal cancer ascitic fluid primary tumour cell culturing method, and matching reagent
KR102089476B1 (ko) 2018-07-11 2020-03-16 이화여자대학교 산학협력단 피부 염증 질환 예방 또는 치료용 조성물
KR102130493B1 (ko) 2018-07-11 2020-07-06 이화여자대학교 산학협력단 건선 예방 또는 치료용 조성물
CN109652377B (zh) * 2019-01-15 2023-03-28 广州医科大学 一种肺癌干细胞的制备方法及应用
WO2021046186A1 (en) * 2019-09-04 2021-03-11 Vcell Therapeutics, Inc. Vaccine for treatment of cancer and method of making by stress reprogramming
KR20190120141A (ko) 2019-10-16 2019-10-23 이화여자대학교 산학협력단 골수 부전 예방 또는 치료용 조성물
CN113069547B (zh) * 2021-04-16 2023-01-24 同济大学附属第一妇婴保健院 Bap1作为肿瘤治疗靶点在制备预防或治疗肿瘤药物中的应用
CN113444690A (zh) * 2021-07-29 2021-09-28 大连大学 一种基于三维培养体系的肿瘤细胞耐照射模型的建立方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US20050136066A1 (en) 1996-06-12 2005-06-23 Yajun Guo Cellular vaccines and immunotherapeutics and methods for their preparation
US7348015B2 (en) 1998-01-14 2008-03-25 Morphogenesis, Inc. Antigen modified cancer cell vaccines for cancer therapy
US6416999B1 (en) 2000-04-07 2002-07-09 Raven Biotechnologies, Inc. Human Müllerian duct-derived epithelial cells and methods of isolation and uses thereof
US6436704B1 (en) 2000-04-10 2002-08-20 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
WO2003032814A2 (en) 2001-10-16 2003-04-24 Raven Biotechnologies, Inc. Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof
JP2005522483A (ja) 2002-04-11 2005-07-28 アルタレックス メディカル コーポレーション 結合剤及び腫瘍細胞をターゲティングする際のそれらの使用
MXPA04012664A (es) 2002-06-19 2005-08-15 Raven Biotechnologies Inc Objetivo de superficie celular raag10 novedoso y una familia de anticuerpos que reconocen ese objetivo.
MXPA06003028A (es) 2003-09-18 2006-06-23 Raven Biotechnologies Inc Medios de cultivo de celulas.
GB0406215D0 (en) 2004-03-19 2004-04-21 Procure Therapeutics Ltd Prostate stem cell
KR101295139B1 (ko) 2004-06-07 2013-08-12 레이븐 바이오테크놀로지스, 인코퍼레이티드 트랜스페린 리셉터 항체
ITRM20040438A1 (it) 2004-09-15 2004-12-15 Univ Palermo Metodo per la purificazione e l'amplificazione di cellule staminali tumorali.
CA3218940A1 (en) 2004-11-12 2006-05-18 Cambridge University Technical Services Ltd. Methods and means related to cancer stem cells
US7687242B2 (en) 2005-01-12 2010-03-30 Raven Biotechnologies, Inc. KID31 and antibodies that bind thereto
WO2006084078A2 (en) 2005-02-02 2006-08-10 Raven Biotechnologies, Inc. Jam-3 and antibodies that bind thereto
AU2006210589B2 (en) 2005-02-02 2011-12-08 Macrogenics West, Inc. ADAM-9 modulators
EP1846455A4 (en) 2005-02-03 2010-02-17 Raven Biotechnologies Inc ANTIBODY TO THE ONKOSTATIN M RECEPTOR
BRPI0607450A2 (pt) 2005-02-04 2009-09-01 Raven Biotechnologies Inc anticorpos que se ligam a epha2 e métodos para sua utilização
US20090012024A1 (en) 2005-07-26 2009-01-08 Procure Therapeutics Limited Stem Cell Markers
US20070123448A1 (en) 2005-11-23 2007-05-31 The Hospital For Sick Children Novel chemical entities affecting neuroblastoma tumor-initiating cells
WO2008039874A2 (en) 2006-09-26 2008-04-03 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
KR101523698B1 (ko) 2007-01-22 2015-05-29 마크로제닉스 웨스트 인코퍼레이티드 사람 암 줄기세포

Also Published As

Publication number Publication date
CN101855339A (zh) 2010-10-06
IL199836A0 (en) 2010-04-15
US8309354B2 (en) 2012-11-13
EP2109668A2 (en) 2009-10-21
JP2010516259A (ja) 2010-05-20
IL199836A (en) 2014-02-27
KR20100033471A (ko) 2010-03-30
AU2008207945A1 (en) 2008-07-31
WO2008091908A3 (en) 2009-12-30
KR101523698B1 (ko) 2015-05-29
CA2675521A1 (en) 2008-07-31
WO2008091908A2 (en) 2008-07-31
US20080175870A1 (en) 2008-07-24
EP2109668A4 (en) 2011-10-05

Similar Documents

Publication Publication Date Title
CA2675521C (en) Human cancer stem cells
JP6207783B2 (ja) 抗原特異的ｔ細胞の増殖のための方法
Grange et al. Sca-1 identifies the tumor-initiating cells in mammary tumors of BALB-neuT transgenic mice
JP6630074B2 (ja) 新規に単離された細胞の治療組成物の操作および送達
CN103756964B (zh) 一种高效扩增cd3-cd56+的自然杀伤细胞培养系统的方法
KR20200003913A (ko) 액상 종양으로부터의 종양 침윤 림프구의 확장 및 그의 치료 용도
KR102944529B1 (ko) 항-pd-1 항체에 불응성인 nsclc 환자의 치료
US20240366664A1 (en) Treatment of cancer with nk cells and an egfr targeted antibody
EP4262830A1 (en) Treatment of cancer with nk cells and a cd20 targeted antibody
CN107541498A (zh) 一种tcr基因修饰的cd8+t记忆性干细胞的制备方法及其用途
IL303762A (en) Expanded and stimulated natural killer cells
EP4426350A2 (en) Treatment of cancer with nk cells and multispecific engagers
KR20160093654A (ko) 종양을 치료하는 방법
TW202208616A (zh) 改良之腫瘤反應性ｔ細胞的選擇
ES2984777T3 (es) Proceso mejorado de cultivo de linfocitos infiltrantes de tumores para uso terapéutico
CN113544262B (zh) 包括细胞因子诱导的杀伤细胞的活化淋巴细胞及其制备方法
CN112972491B (zh) 癌症治疗或预防用细胞组合物、及其制造方法
EP4183872A1 (en) Immunotherapy method of targeted chemokine and cytokine delivery by mesenchymal stem cell
US12440565B1 (en) Dendritic cell preparation and preparation method thereof
US10022402B2 (en) Allogenic mesendritic vector for ovarian cancer
JP7733640B2 (ja) 不死化された筋芽細胞株及びその使用
Ge et al. Vaccination with immature dendritic cells combined with CD40 mAb induces protective immunity against B lymphoma in hu-SCID mice
HK40059384B (zh) 包括细胞因子诱导的杀伤细胞的活化淋巴细胞及其制备方法
WO2025096638A2 (en) Genetically modified tumor infilitrating lymphocytes and methods of producing and using the same
Jæhger Preclinical Evaluation of Novel Drug Delivery Platforms for the Improvement of Adoptive T cell Therapy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130121

MKLA Lapsed

Effective date: 20190122